Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Gruber

Showing results (271-280 of 355) with videos related to

Pageof 36
Sort By:
The Journal of Infectious Diseases|November 15, 2014
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide VaccineMarshall J Glesby, Wendy Watson, Cynthia Brinson, et al.
Vaccine|January 24, 2024
A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and TaiwanMiwa Haranaka, Joon Young Song, Kuo-Chin Huang, et al.
Vaccine|September 13, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccineK A Bryant, R Frenck, A Gurtman, et al.
The Pediatric Infectious Disease Journal|January 22, 2000
Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretionsR Malley, L Vernacchio, J Devincenzo, et al.
Clinical and Vaccine Immunology : CVI|April 30, 2010
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlersSusanna Esposito, Susan Tansey, Allison Thompson, et al.
Open Forum Infectious Diseases|January 30, 2020
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel <i>Staphylococcus aureus</i> 4-Antigen Vaccine (SA4Ag)C Buddy Creech, Robert W Frenck, Anne Fiquet, et al.
The Pediatric Infectious Disease Journal|August 16, 2014
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of ageJanusz Gadzinowski, Susan P Tansey, Jacek Wysocki, et al.
The Journal of Infectious Diseases|May 11, 2022
A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older AdultsJames Baber, Mark Arya, Yuben Moodley, et al.
The Journal of Infectious Diseases|December 21, 2021
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza VaccineAnn R Falsey, Edward E Walsh, Daniel A Scott, et al.
Human Vaccines & Immunotherapeutics|November 6, 2023
Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trialMichael W Simon, Regine Bataille, Nicole S Caldwell, et al.
Pageof 36

Showing results (271-280 of 355) with videos related to

Sort By:
Pageof 36
The Journal of Infectious Diseases|November 15, 2014
Immunogenicity and Safety of 13-Valent Pneumococcal Conjugate Vaccine in HIV-Infected Adults Previously Vaccinated With Pneumococcal Polysaccharide VaccineMarshall J Glesby, Wendy Watson, Cynthia Brinson, et al.
Vaccine|January 24, 2024
A phase 3 randomized trial of the safety and immunogenicity of 20-valent pneumococcal conjugate vaccine in adults ≥ 60 years of age in Japan, South Korea, and TaiwanMiwa Haranaka, Joon Young Song, Kuo-Chin Huang, et al.
Vaccine|September 13, 2015
Immunogenicity and safety of a 13-valent pneumococcal conjugate vaccine in adults 18-49 years of age, naive to 23-valent pneumococcal polysaccharide vaccineK A Bryant, R Frenck, A Gurtman, et al.
The Pediatric Infectious Disease Journal|January 22, 2000
Enzyme-linked immunosorbent assay to assess respiratory syncytial virus concentration and correlate results with inflammatory mediators in tracheal secretionsR Malley, L Vernacchio, J Devincenzo, et al.
Clinical and Vaccine Immunology : CVI|April 30, 2010
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine compared to those of a 7-valent pneumococcal conjugate vaccine given as a three-dose series with routine vaccines in healthy infants and toddlersSusanna Esposito, Susan Tansey, Allison Thompson, et al.
Open Forum Infectious Diseases|January 30, 2020
Persistence of Immune Responses Through 36 Months in Healthy Adults After Vaccination With a Novel <i>Staphylococcus aureus</i> 4-Antigen Vaccine (SA4Ag)C Buddy Creech, Robert W Frenck, Anne Fiquet, et al.
The Pediatric Infectious Disease Journal|August 16, 2014
Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine manufactured with and without polysorbate 80 given to healthy infants at 2, 3, 4 and 12 months of ageJanusz Gadzinowski, Susan P Tansey, Jacek Wysocki, et al.
The Journal of Infectious Diseases|May 11, 2022
A Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine With and Without Adjuvant in Healthy Older AdultsJames Baber, Mark Arya, Yuben Moodley, et al.
The Journal of Infectious Diseases|December 21, 2021
Phase 1/2 Randomized Study of the Immunogenicity, Safety, and Tolerability of a Respiratory Syncytial Virus Prefusion F Vaccine in Adults With Concomitant Inactivated Influenza VaccineAnn R Falsey, Edward E Walsh, Daniel A Scott, et al.
Human Vaccines & Immunotherapeutics|November 6, 2023
Safety and immunogenicity of a multivalent pneumococcal conjugate vaccine given with 13-valent pneumococcal conjugate vaccine in healthy infants: A phase 2 randomized trialMichael W Simon, Regine Bataille, Nicole S Caldwell, et al.
Pageof 36